Study of lymph node MRI (magnetic resonance imaging) agent completed:
This article was originally published in Clinica
Advanced Magnetics has said it will file a new drug application with the FDA next year for its MRI contrast agent Combidex, following the completion of Phase III clinical trials. The Cambridge, Massachusetts-based company plans to market the agent for assisting in the diagnosis and staging of metastatic disease in lymph nodes as well as for detecting and characterising liver lesions.
You may also be interested in...
New rules in India specify that a marketer of a drug will share the onus for quality and compliance along with the manufacturer. Enhanced punishment for misleading advertisements for a range of illnesses is also proposed, while calls for a statute to regulate pharma's marketing practices grow louder.
Former managing director of Janssen India to helm Bharat Serums and Vaccines following the firm’s acquisition by private equity firm Advent International.